Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night-time awakenings in moderate to severe COPD: results from a 1-year study Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002
Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1-year study Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
The effectiveness of chest physiotherapy that is applied in COPD patients with exacerbation Source: Eur Respir J 2006; 28: Suppl. 50, 627s Year: 2006
Do patients with asthma cough more frequently at night during impedance/pH monitoring than other patients with chronic cough? Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions Year: 2019
Evolution of intensity and quality of exertional dyspnea in patients with stable asthma Source: Annual Congress 2010 - Interaction between respiratory and peripheral muscles Year: 2010
Shortness of breath, cough, and right-sided chest pain in a child Source: International Congress 2016 – GR1 Paediatric Grand Round Year: 2016
Budesonide/formoterol in a single inhaler rapidly improves lung function in adult patients with mild or moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
The relationship between the lung function and dyspnea, cough, and exercise capacity in the not-treated COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 511s Year: 2005
Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study Source: Eur Respir J 2014; 43: 1599-1609 Year: 2014
An interesting case of recurrent shortness of breath and pleuritic chest pain Source: Breathe, 14 (2) 123; 10.1183/20734735.012118 Year: 2018
Effects of arm training on exertional dyspnoea in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 66s Year: 2002
Chronic cough: objective cough frequency in a large cough clinic cohort Source: International Congress 2017 – Notable abstracts in asthma Year: 2017
Pretreatment with inhaled procaterol improves symptoms of dyspnea and quality of life in patients with severe COPD Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Mechanisms of dyspnoea relief following radiation treatment in a patient with severe COPD Source: Eur Respir J 2011; 38: 728-730 Year: 2011
How to quantify coughing: correlations with quality of life in chronic cough Source: Eur Respir J 2008; 32: 175-179 Year: 2008